Patients with pancreatic cancer who present high levels of MAP17 exhibit worse overall survival, a finding supported by the increased resistance of MAP17-expressing tumors to classical treatments such as cisplatin, 5FU, or gemcitabine administered in vivo. This evidence concerns the gene PDZK1IP1 and pancreatic neoplasm.